This Acquirers Multiple Stock Is Appearing In Dalio, Simons, Ainslie, Portfolios

Johnny HopkinsStock ScreenerLeave a Comment

Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:

Quest Diagnostics Inc (NYSE: DGX)

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

A quick look at the price chart below for Quest Diagnostics shows us that the stock is up 9% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 8.44, which means that it remains undervalued.

(Source: Google)

Superinvestors who currently hold positions in Quest Diagnostics include:

(Shares)

Chris Davis – 2,778,106

Jeremy Grantham – 1,539,355

Cliff Asness – 512,701

Israel Englander – 314,137

Jim Simons – 268,700

Ray Dalio – 62,176

Rob Olstein – 62,000

Paul Tudor Jones – 53,597

Ken Griffin – 51,381

Joel Greenblatt – 26,077

Charles Brandes – 7,380

Murray Stahl – 4,812

Lee Ainslie – 2,441

For all the latest news and podcasts, join our free newsletter here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:

unlimited

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.